Released on = July 3, 2006, 6:12 am

Press Release Author = 121Doc.co.uk

Industry = Healthcare

Press Release Summary = Acomplia Rimonabant by Sanofi - Aventis, the much awaited
anti-obesity drug was launched in Europe last week after more than two years of
clinical trials and tests on humans.

Press Release Body = Acomplia, the brand name of Rimonabant has been developed by
the French Pharmaceutical giant Sanofi-Aventis to act as a major deterrent to
increasing obesity and smoking. Although it has been permitted to be marketed only
as a anti-obesity drug it possesses wondrous properties of curbing smoking and
persuade heavy smokers to relinquish the habit as per clinical test results. This
drug Acomplia Rimonabant acts on the complex mechanism of the human brain and
simultaneously it acts on the nerve cells that control the energetic mechanism of
the body. It acts on the part of the brain that is responsible for the pleasurable
feeling usually associated with eating a good meal or smoking nicotine or marijuana.


The chemical compounds called Cannabinoids, latch on to the overactive CB1 receptors
in overweight and obese individuals, and send out a signal that prompt people to eat
more and in the process makes them overweight. Cannabinoid receptor's, part of the
Endocannabinoid system in the brain play a critical role in the regulation of food
intake and energy expenditure of our body and are present in the brain and fat
cells. Acomplia Rimonabant blocks the CB1 receptors thus reducing the cravings and
the urge to overeat and smoke. Diet pill Acomplia Rimonabant prevents action of
cannabinoid receptors and in this process curbs appetite.
Various clinical tests and trials have shown results where acomplia rimonabant helps
in significantly decreasing body weight and waist. Acomplia rimonabant helps in
improving lipid and glucose profiles. Acomplia Rimonabant improves a variety of
cardiometabolic risk factors in obese and overweight people such as HDL cholesterol,
triglycerides and insulin resistance. Based on various tests it was observed that
lipid profile changes with a 23% increase in HDL-cholesterol (good cholesterol) and
a 15% decrease in triglycerides. Usage of Acomplia Rimonabant discouraged smoking
even in heavy smokers owing. Acomplia Rimonabant also improves glucose tolerance and
increase in insulin levels. Summing up the Acomplia Rimonabant advantages, it can
fight obesity, kill the urge to smoke, stop cocaine addiction and obliterate
marijuana and alcohol cravings.

Irritability, depression and nausea were few of the symptoms observed as side
effects of taking Acomplia. Most of those are short lived and disappear in a very
short period of time. The symptoms of staying fat have much worse consequences than
anything that has come up in the study of Acomplia Rimonabant side effects.
Obesity, smoking, etc. can greatly reduce the lifespan of people. Side effects, due
to Acomplia Rimonabant are minor as compared to the enormous benefit caused by
taking Acomplia Rimonabant. Acomplia Rimonabant reduces body weight and discourages
smoking which can be the biggest incentive of all. Only a minor percentage of people
who participated in the trials faced any side effects and acomplia rimonabant
advantages are too many to be disregarded


Web Site = http://www.121doc.co.uk

Contact Details = 121doc,
Kristian Lane,
h45k57
44-9377175492
healthexp@gmail.com